Nuevolution AB (publ) intends to move the listing of its shares to Nasdaq Stockholm’s main market during the fiscal year 2017/18

Stockholm, 18 September 2017 — Nuevolution AB (publ), a leading small-molecule drug-discovery biotech company listed on Nasdaq Stockholm First North Premier (NUE.ST), today announced that the company intends to move the listing of its shares to the Nasdaq Stockholm’s main market in fiscal 2017/18.

Following a review of Nuevolution’s business strategy, the Board of Directors is of the opinion that the time is appropriate to move the listing of the Company’s shares to a regulated market. This forms an important part of the Company’s strategy “Grand plan – Reaching New Horizons”.

‘The listing of Nuevolution’s shares on Nasdaq Stockholm’s main market has been an outspoken ambition and target, ever since the shares were listed on Nasdaq First North Premier in December 2015. Today, we announce that we plan for this to happen in the fiscal year 2017/18. This is a natural progression of the Company’s strategy laid out in connection with the IPO in 2015,’ stated CEO Alex Haahr Gouliaev.

More details behind this decision and information about Nuevolution’s “Grand Plan – Reaching New Horizons” can be found in the Annual report 2016/17, released today and available on the Company’s homepage www.nuevolution.com

To support a successful change of listing, Nuevolution has engaged Carnegie Investment Bank as financial advisor, Advokatfirman Vinge as legal advisor and E&Y for a pre-IPO review.

For more information, please contact:
Alex Haahr Gouliaev, CEO
Phone: +45 3913 0902
Email: [email protected]

Henrik Damkjær Simonsen, CFO
Phone: +45 3913 0947
Email: [email protected]

 

Information about Nuevolution AB (publ)

Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, and headquartered in Copenhagen, Denmark. Nuevolution partners its discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit of patients in need of novel medical treatment option. Nuevolution’s internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology.

This information is information that Nuevolution AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Market Act. The information was sent for publication, through the agency of the contact persons set out above, on Monday 18 September 2017 at 8:30 CEST.

Nuevolution AB (publ) is listed at Nasdaq First North in Stockholm, Sweden (ticker: NUE). Redeye AB acts as Certified Advisor to Nuevolution AB (publ). More information about Nuevolution can be found on: www.nuevolution.com.